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BACKGROUND: Side population (SP) fraction cells, identified by efflux of Hoechst dye, are present in virtually all normal and malignant
tissues. The relationship between SP cells, drug resistance and cancer stem cells is poorly understood. Small-cell lung cancer (SCLC) is
a highly aggressive human tumour with a 5-year survival rate of o10%. These features suggest enrichment in cancer stem cells.
METHODS AND RESULTS: We examined several SCLC cell lines and found that they contain a consistent SP fraction that comprises o1%
of the bulk population. Side population cells have higher proliferative capacity in vitro, efficient self-renewal and reduced cell surface
expression of neuronal differentiation markers, CD56 and CD90, as compared with non-SP cells. Previous reports indicated that
several thousand SP cells from non-small-cell lung cancer are required to form tumours in mice. In contrast, as few as 50 SP cells from
H146 and H526 SCLC cell lines rapidly reconstituted tumours. Whereas non-SP cells formed fewer and slower-growing tumours, SP
cells over-expressed many genes associated with cancer stem cell and drug resistance: ABCG2, FGF1, IGF1, MYC, SOX1/2, WNT1,a s
well as genes involved in angiogenesis, Notch and Hedgehog pathways.
CONCLUSIONS: Side population cells from SCLC are highly enriched in tumourigenic cells and are characterised by a specific stem cell-
associated gene expression signature. This gene signature may be used for development of targeted therapies for this rapidly fatal
tumour.
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Small-cell lung cancer (SCLC) is the most devastating type of
human lung cancer. In spite of recent decline in frequency, it still
accounts for approximately 12% of the 220000 new lung cancer
cases projected for 2009 (Jemal et al, 2009). These patients usually
present with disseminated disease to many organs, including the
brain, and their initial response to therapy is rapidly followed by a
relapse with drug-resistant disease. Small-cell lung cancer is a
neuroendocrine tumour composed of cells capable of differentia-
tion into neuronal and endocrine lineages, thus bridging two
unrelated organ systems. It has high proliferative capacity, with a
doubling time estimated to be as fast as 38 days in humans (Sone
et al, 2007). The aggressive nature of SCLC combined with the
capacity for differentiation into multiple lineages and the
development of resistant disease suggest that this tumour may
be enriched in cells with cancer stem cell-like characteristics. There
is no previous information on the nature of cancer stem-like cells
in small-cell lung cancer.
The existence of cancer stem cells was proposed over 30 years
ago (Hamburger and Salmon, 1977) and has been fully established
for haematological malignancies (Kondo et al, 2003; Wang
and Dick, 2005). However, the origin and biology of cancer
stem cells from solid tumours is still actively debated. As cancer is
believed to be clonal in origin, it has been suggested that
cancer-initiating cells undergo processes analogous to self-renewal
and differentiation of normal stem cells, which are characterised
by the ability to reconstitute the entire spectrum of cells by
asymmetric division (Al Hajj and Clarke, 2004; Caussinus and
Gonzalez, 2005; Hadnagy et al, 2006; Patrawala et al, 2006). Thus,
similar to normal adult stem cells, cancer-initiating or cancer
stem-like cells comprise only a fraction of the total tumour cell
population. A recent analysis of many cell lines and clinical
samples from breast, prostate and other tumours has indicated
that they contain a small fraction of cells identified by a variety of
cell surface markers, expression of stem cell genes, reconstitution
of tumours in vivo and enhanced drug resistance (Sales et al,
2007). The frequency of tumour-initiating cells varies from 27 to
100% in highly tumourigenic, haematopoietic and melanoma
primary tumours and in some cell lines (Kelly et al, 2007; Quintana
et al, 2008), but it is reported to be less than 1% for most
solid tumours. These differences have important clinical implica-
tions and highlight the importance of continuing the search
for commonality among cancer stem cells from individual
tumour types.
The ability to exclude Hoechst dye as defined by side population
(SP) fraction was initially described in normal haematopoietic cells
(Goodell et al, 1996), but was subsequently found to be present in
haematopoietic malignancies and solid tumours (Hadnagy et al,
2006). Side population cells comprise less than 0.1% of the
whole bone marrow cells and are enriched in drug-resistant
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shaematopoietic stem cells (Sales et al, 2007). Several important
stem cell features have been associated with the SP fraction cells:
first, the ability to exclude Hoechst dye has been associated with
higher expression of drug transporters, primarily of the ABC
transporters family, such as ABCB1 (MDR1) and ABCG2 (BCRP),
which are capable of extrusion of the dye from the cell (Goodell
et al, 1996; Kim et al, 2002). Second, expression of ABC
transporters is associated with drug resistance that is characteristic
of stem cells from normal and malignant tissues (Szakacs et al,
2006). Third, the SP fraction cells are enriched in cells capable of
self-renewal and differentiation with reconstitution of the original
cell population (Al Hajj and Clarke, 2004; Hadnagy et al, 2006).
Therefore, they may have a pivotal role in normal development
and stem cell biology. These fundamental characteristics of normal
stem cells have been applied to cells isolated from SP fraction in
multiple tumours (Hadnagy et al, 2006; Ho et al, 2007), but have
not been characterised in SCLC.
Owing to an aggressive clinical course and disseminated disease
at presentation, patients with SCLC almost never undergo tumour
resection. The diagnosis is virtually always performed on a scant
material obtained by thin needle biopsy, and therapy is initiated
immediately after the sample collection. Thus, there is no access to
tissue samples for analysis of stem cell population in this disease.
However, SCLC cells readily grow in vitro and numerous cell lines
have been established from patients with SCLC. In contrast to
other solid tumors, most SCLC cell lines do not require
attachment, grow as clusters in suspension and are highly
tumourigenic. Thus, studies on SCLC cell lines can be uniquely
suited for examination of the cancer stem cell population. We
found that SP fraction cells are substantially enriched in tumour-
initiating or cancer stem-like cells that can be defined by
functional analysis and by expression of cancer stem cell and
drug resistance genes.
MATERIALS AND METHODS
Cells
The human SCLC cell lines NCI-H82, H146 and H526, as well as the
non-small-cell lung cancer lines A549 and H460, were obtained
from ATCC and maintained at 0.5 10
6–2 10
6cellsml
 1 in
complete media consisting of RPMI 1640 supplemented with 10%
fetal bovine serum (Lonza, Corp, NY, USA), glutamine and 1%
penicillin–streptomycin (Invitrogen, Carlsbad, CA, USA) in a
humidified 37
oC incubator with 5% CO2.
SP fraction in vitro analysis by proliferation and
limiting dilution
Cells were labelled with Hoechst 33342 dye (Molecular Probes,
Invitrogen) according to Goodell et al, (1996) with minor
modifications. Briefly, cells were suspended in pre-warmed
RPMI-1640 containing 2% FBS and 2mM HEPES (HBSS) at
1 10
6 cellsml
 1 for 20min and incubated for an additional
90min at 371C in a shaking bath with 5mgml
 1 (8.1mM) Hoechst
33342 dye. Control cells were incubated with 50mM Verapamil
(Sigma, St Louis, MO, USA) for 15min at 371C before Hoechst dye
addition. Cells were placed immediately on ice, washed and
resuspended in cold HBSS containing 1% BSA. After gating viable
cells identified by 7-AAD at 20mgml
 1 (BD Pharmingen,
Lexington, KY, USA), SP and non-SP fractions were gated
separately and analysed using an LSRII flow cytometer
(BD Biosciences, San Jose, CA, USA).
For limiting dilution assay in vitro, sorted cells were plated 50ml
per well in 96-well plates in complete media. The media was added
biweekly for the following 2 weeks and colonies were scored.
Proliferative capacity was determined by plating o2 cells per well
and the media was added as above. The number of wells that
contained colonies was scored at the end of 3 weeks.
Cell surface immunophenotyping
Immunophenotyping was carried out using conjugated mono-
clonal human antibodies reactive to CD24, 34, 44, 45, 56, 87, 90,
117, 133, CXCR4, ABCB1 and ABCG2 (BD Pharmingen). The
staining was performed in the dark at 41C for 30min. Isotype
control antibodies and live unstained cells were used to establish
gating parameters for positive cells. Mean fluorescence intensity
(MFI) was determined using FlowJo Software (NCI license, Asland,
OR, USA).
Stem cell gene expression by focused array
The mRNA levels of 84 genes associated with stem cell biology
were examined simultaneously using human Stem Cell RT
2 profiler
arrays (SuperArray Bioscience, Frederick, MD, USA) according to
the manufacturer’s instructions. Briefly, total RNA was isolated
using TRIzol (Invitrogen) followed by spin-column purification
with RNeasy extraction kit (Qiagen, Valencia, CA, USA) in the
presence of DNAse. Total RNA (250ng) was reverse transcribed
using the First Strand Synthesis Kit and cDNA was subjected to
real-time PCR using SYBR green/ROX Master Mix on a 7500 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA).
Values obtained for the threshold cycle (Ct) for each gene were
normalised using the average of values of housekeeping genes. The
difference (DCt) between SP and non-SP RNA values was
determined by DCt¼Ct(SP)–Ct(non-SP) and fold change by fold
change¼2( DCt).
Validation of gene expression by quantitative-PCR
Quantitative-PCR (Q-PCR) analysis was carried out using TaqMan
probes (Applied Biosystems) according to the manufacturer’s
instructions, in a 10ml final reaction volume using 384-well
microtitre plates. One microgram of total RNA was reverse
transcribed into cDNA using the Single-Strand cDNA Synthesis
Kit (Stratagene, La Jolla, CA, USA) and analyzed using ABI-7900
(Applied Biosystems, Foster City, CA, USA). Specific primers for
Q-PCR of GAPDH, RPL13A and ACTB (housekeeping genes) and
the additional genes of interest (Figure 5) were designed using
Applied Biosystems Assay-by-Design primer design software or
were purchased as Assays-on-Demand from Applied Biosystems.
Quantification of each mRNA was achieved by normalising the
sample values to the universal Stratagene (Novoradovskaya)
reference from human liver. The samples were normalised to
human GAPDH, RPL13A and ACTB individually, as well as to the
average of all three endogenous controls. The expression level of
each gene in the SP was compared with the corresponding level in
non-SP fractions in triplicates from three independent experiments.
In vivo tumour formation
All studies were conducted in an AAALAC-accredited facility, in
compliance with the US Public Health Service guidelines for the
care and use of animals in research under protocols approved by
the ACUC. Naive male 6–8-week-old NOD/SCID mice from the
NCI Animal Production Program (NCI-Frederick, Frederick, MD,
USA) or Jackson Laboratories (Bar Harbor, ME, USA) were used as
tumour transplant recipients. For in vivo tumour formation,
growing cells sorted from the SP and non-SP fractions or the bulk
population, diluted in PBS, were mixed with 50ml Matrigel (BD
Bioscences) and injected subcutaneously. Tumour growth was
measured biweekly and the weights (in milligrams) were calculated
using the formula for a prolate ellipsoid and assuming a specific
gravity of 1.0gcm
 3 using the formula L W
2 0.5 (Plowman
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set al, 1997). For isolation of cells from xenografts, freshly isolated
tumours were made into single-cell suspension as described
(Varticovski et al, 2007).
Statistical methods
Differences were determined using two-tailed non-paired t-test or
by two-sided Fisher’s exact test, as indicated in the text.
RESULTS
SCLC cell lines contain a side population that excludes
Hoechst dye (SP fraction)
We examined H82, H146 and H526 SCLC cell lines by flow
cytometry of live cells for exclusion of Hoechst dye, and defined
the gating of these cells by disappearance of this fraction in cells
pre-incubated with the transporter inhibitor, Verapamil. All SCLC
cell lines examined contained less than 1% in SP fraction. H146
cells contained 0.8±0.1 and H526 had 0.9±0.4% of SP cells in the
total cell population (Supplementary Figure 1). Supplementary
Figures 1A and B also illustrate the SP gating for H146 and H526
cells, wherein the gating is defined by pretreatment with
Verapamil. Mouse bone marrow cells with an SP fraction of
0.1% were used as a positive control and are shown on the lower
panel. As previously reported (Ho et al, 2007), the non-small-cell
lung cancer cell lines A549 and H460 have a higher SP fraction (2–
4%) (Supplementary Figure 2). We also tested cells isolated from
SP and non-SP fractions for viability after exposure to Hoechst dye
at concentrations used in these studies using MTT dye staining
(Wright et al, 2008), and found no impairment of cell viability.
Previous studies indicated that expression of ABC transporters
was associated with the SP fraction and expression of ABCG2 was
described to be associated with normal and malignant stem cells
(Farnie and Clarke, 2007; Ho et al, 2007). Although there was a
small increase in ABCB1 and ABCG2 transporters in SP fraction
cells in some experiments (Supplementary Figure 2B), we found no
statistically significant differences on repeated experiments and
none of the other SCLC cell lines examined had significant cell
surface expression of ABCB1 or ABCG2 (data not shown).
To determine the differences in proliferation, cells were isolated
by sorting from the SP and non-SP fractions and plated by limiting
dilution from 500 to 1 cell per well in 96-well plates in replicates of
six wells in complete growth media. Cells isolated from the SP
fraction were more likely to survive and form viable colonies at the
end of 3 weeks. We did not see appreciable differences in colony
size formed by SP and non-SP cells, but noted that SP fraction cells
grew colonies even when plated at very low cell density number
(Figure 1A).
Self-renewal capacity of SP and non-SP cells
To determine differences in self-renewal capacity of cells from SP
and non-SP fractions, 10000 cells were isolated from each fraction
and cultured for 2–3 weeks until the total cell number was
increased to approximately one million cells, a number required
for adequate SP analysis. Of 100% SP cells sorted at the beginning
of the experiment, only 3% remained after 17 days in culture
(Figure 1B). These data indicate that the absolute number of SP
cells was retained in the expanded population, and the overall
population lost the ability to efflux Hoechst dye. Interestingly,
non-SP cells also acquired a small SP fraction within 17 days.
Extending the period of observation to 6 weeks resulted in
reconstitution of the original populations observed in unsorted
cells, with o1% of cells in SP fraction (data not shown).
Considering that the doubling time for H146 cells is approximately
30–36h, the SP fraction cells preserved self-renewal without
appreciable expansion in vitro. These observations also suggest
that the non-SP cells acquire SP function or that the gating cells
solely based on flow cytometry do not allow absolute separation of
these cells. These data confirm that Hoechst dye labelling and
separation by flow cytometry are not exclusive.
Expression of cell surface markers in SP and non-SP cells
To further define the cells within the SP fraction, we used multiple
cell surface markers described in association with neuroendocrine
tumours and cancer stem cells (see Materials and Methods). The
analysis of three SCLC lines (H82, H146 and H526) revealed that
these cells differ significantly in expression of cell surface markers.
Only a few markers such as CD56 (N-CAM, neural cell adhesion
molecule 1 isoform, a hallmark of SCLC), CD90 (Thy-1, a neuronal
and mesenchymal stem cell marker), CXCR4 (metastasis-asso-
ciated G-protein receptor) and CD44 (associated with breast and
other CSCs) were expressed in all cell lines, whereas expression of
CD133, associated with cancer stem cells in many other tumour
types (Mizrak et al, 2008), including non-small-cell lung cancer
(Eramo et al, 2008), varied from nearly 100% positive in H82 to
20% in H146 and was non-detectable in H526 cells. However, we
found that the overall percent of cells positive for CD56 was
significantly lower in SP as compared with non-SP cells in all cell
lines examined, as shown for the H146 and H526 cells in Figure 2.
Although the decrease in CD90 cell surface expression in the SP
fraction in H146 cells was small, it was statistically significant
and substantially different in H526 and H82 (Figure 2, data not
shown). In addition, measurements of MFI were lower in SP cells
(Figure 2B and Supplementary Table I), indicating lower cell
surface protein expression per cell. No statistically significant
changes in other cell surface proteins, including ABCG2, CD133
and CD44, were observed in these cells.
SP fraction cells are enriched in tumour-initiating
cells in vivo
We tested tumour reconstitution in vivo using a limiting dilution
of cells sorted from the SP and non-SP fractions. We did not use
additional markers because we did not find additional markers for
positive selection that are common to the SCLC cell lines. As seen
in Figure 3 and Supplementary Figure 3, as few as 50–100 SP cells
from H146 and H526 cells, respectively, were sufficient to rapidly
reconstitute the tumours, whereas mice that received 50–100 non-
SP cells did not develop tumours, or had only palpable tumours in
the same time frame (less than 5mm
3). All mice implanted with
500 SP cells rapidly developed tumours that had to be removed
within 3–4 weeks, whereas mice that received non-SP cells (5 of 9)
had only small tumours in that period of time. These non-SP
tumours grew considerably slower and reached 300–500cm
2 size
after additional 30 days of observation. Thus, SP fraction cells are
considerably more efficient in tumour reconstitution in vivo. The
tables in Figure 3 and Supplementary Figure 3 summarise the
results of multiple independent experiments showing the fre-
quency of tumour formation by SP and non-SP cells obtained from
H146 and H526 cell lines, respectively. The major differences in
tumour-initiating frequency between SP and non-SP cells are
apparent at low numbers of injected cells (50–100). We conclude
that, in spite of minor differences in growth rates in vitro, the SP
fraction cells are significantly enriched in tumour-initiating cells.
Analysis of SP fraction from xenografts formed by SP fraction cells
showed that these tumours returned to the original proportion of
SP cells, with a very small (o1%) SP fraction. This is consistent
with our in vitro self-renewal data and observations from
other investigators in other tumour types (Wright et al, 2008;
Eramo et al, 2008).
The H&E stain was performed on tumours formed by equal
numbers of SP and non-SP cells when they reached comparable
tumour size. This analysis revealed the features and characteristics
Cancer stem cells in SP fraction
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sof SCLC tumours with hyperchromatic nuclei, abundant cyto-
plasm, finger-like projections and frequent mitotic figures with no
significant differences in morphology between SP and non-SP
formed tumours (Supplementary Figure 4). We also found no
evidence of metastasis into lung, liver and other major organs by
gross pathological examination. Staining for Ki67 also did not
reveal significant differences. Although the vascular structure of
tumours formed by SP cells was somewhat more pronounced, it
was not readily apparent on all sections and all tumours examined.
However, analysis of vascular staining using mouse endothelial cell
marker, CD31, showed that SP tumours had an abundant
angiogenic response, were punctate and tortuous staining of
microvessels that was not apparent in tumours formed by non-SP
cells (Figure 4). Quantitative analysis of fluorescence intensity
using computer-generated random fields from several tumours
confirmed a significant increase in the overall intensity of staining
in tumours formed by SP as compared with non-SP cells (Figure 4,
lower panel).
Analysis and validation of gene expression in SP and
non-SP cells
Analysis of stem cell genes To examine the expression of stem cell
genes from cells in SP and non-SP fractions, real-time quantitative
RT–PCR on 84 genes was carried out using commercially available
Stem Cell RT
2 ProfilerTM PCR Focused Array (SuperArray
Bioscience Corp, Frederick, MD, USA) by using two biological
replicates from H146 cells. The list of all 84 stem cell genes on that
panel can be found at http://www.sabiosciences.com/howpcrarray-
works.php. Twenty-two genes were significantly upregulated in SP
as compared with the non-SP cells (Supplementary Table II),
whereas two genes, both associated with cell–cell interactions,
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Figure 1 Characterisation of cells from SP and non-SP fractions. (A) Side population cells have higher proliferative capacity in vitro. H146 cells were sorted
from SP and non-SP populations and plated by limiting dilution in six-tuplicate wells. The number of growing colonies at the end of 3 weeks was scored and
data (expressed as mean number of colonies per well) were averaged from two independent experiments±s.e. Open bars: SP cells; solid bars: non-SP cells.
(B) Cells sorted from SP fraction repopulate the original population. Side population and non-SP cells were sorted according to Verapamil gating (upper
panels) and cultured for 17 days (lower panels).
Cancer stem cells in SP fraction
CD Salcido et al
1639
British Journal of Cancer (2010) 102(11), 1636–1644 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swere downregulated (GJB1 and PARD6A). Overall, there were more
upregulated stem cell genes in SP cells. These features are
consistent with previous reports on enrichment in genes associated
with growth and developmental pathways in SP cells from normal
tissues (Behbod et al, 2006, 2006; Larderet et al, 2006). In addition,
several of the upregulated genes, including ABCG2, BMP1/2, FGF1,
IGF1, MYC, SOX1/2, WNT1 and NOTCH2, have been recently
associated with cancer stem cells and tumour-initiating cells in
lung cancer and other tumour types, as well as with epithelial-to-
mesenchymal transition in tumours with poor prognosis (Fan
et al, 2006; Moustakas and Heldin, 2007). Interestingly, upregula-
tion of ABCG2 transporter mRNA did not correlate with the level
of cell surface protein.
Validation by quantitative RT—PCR Using independent quanti-
tative RT–PCR, we validated few of the significantly changed genes
as well as examined additional genes associated with tumour
progression, angiogenesis and stem cell characteristics that were
not included in the SuperArray panel. We used the same RNA
samples as for the SuperArray and additional samples from
biological replicates from three independent paired sorts of SP and
non-SP cells. The values shown in Figure 5 were normalised to the
three housekeeping genes and to the expression in universal
standard (human liver). The increase in expression of BMP1 and
MYC in SP cells was remarkably similar to the SuperArray data
(Figure 5). In addition, upregulation of other stem cell and
pluripotency-associated genes, KLF4, NANOG, NUMB, OCT4 and
NOTCH1, in SP cells became apparent by this analysis. An increase
in VEGF expression in the SP fraction (Figure 5) and their
xenografts (data not shown) could be responsible for the
substantial angiogenic response in vivo. The high expression of
CXCR4 in SP cells, together with the increase in its ligand CCL12
(SDF-1) detected by SuperArray analysis (Supplementary Table II),
also suggests that these cells have higher migration and metastatic
potential (Das et al, 2008).
Correlation with protein expression To further validate these
results, we examined cell surface protein levels for those proteins
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Figure 2 Expression of differentiation markers is decreased in SP fraction. (A) Percent cell surface expression of CD56 and CD90 within the SP and
non-SP cells in H146 and H526 cells. Solid bars: SP cells; open bars: non-SP cells±s.d. The differences between each pair are statistically significant as
determined by the two-tailed Fisher ‘s t-test, indicated by P values above. (B) Cell surface expression in H146 and H526 cells for each marker using PE-labelled
antibodies. The dashed line represents cells in SP fraction, and the solid line shows cells in non-SP fraction. The filled area represents unstained cells.
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sfor which we had antibodies suitable for flow cytometric analysis.
Although the function of CD8b chain is not well defined, we
included this protein in the analysis as it has a role in chromatin
modifications and alterations in its consensus coding sequences
have been found in human breast and colorectal cancers (Sjo ¨blom,
2006). Expression of three proteins examined (IGF1, FGF1 and
CD8b) was increased in H146 SP cells by 1.2–4.0 fold, with a
corresponding increase in MFI. Cell surface expression of CD8b
and FGF1, but not that of IGF1, was also increased in the SP
fraction of H526 cells (data not shown).
DISCUSSION
We observed novel features in a sub-population of SCLC SP
fraction cells that have cancer stem cell-like characteristics.
Previous studies using SP fractions from many tumours showed
relative enrichment in tumour-initiating cells, but several hundred
or thousand cells were required for tumour reconstitution (Al Hajj
et al, 2003; Collins et al, 2005; Ponti et al, 2005). In studies of non-
small-cell lung cancer, 1–5 10
3 SP cells (Ho et al, 2007) or
1 10
4cells that express CD133 markers (Eramo et al, 2008) were
needed for tumour reconstitution. In contrast, we found that as
few as 50–100SP cells from SCLC lines were sufficient to
reconstitute tumours in NOD/SCID mice, whereas at least 500
non-SP fraction cells were required to form tumours under the
same conditions, although few of those tumours reached 300–
400cm
2 after an additional 30 days of observation. Implantation of
50–100 non-SP cells resulted in either no tumour or formation of
barely palpable tumours that did not progress during the
additional 30 days of observation. A recent report showed that
as little as 10 cells co-implanted with one million unselected
immune cells reconstitute haematopoietic tumours in syngeneic
recipients (Kelly et al, 2007). The differences with reports from
solid tumours were attributed to use of a syngeneic model.
However, studies comparing tumour growth rates of cells from
transgenic Wnt1 mouse mammary tumours implanted into
syngeneic, nude or SCID mice did not show appreciative
differences (Varticovski et al, 2007; Svirshchevskaya et al, 2008).
Thus, the high capacity of tumour reconstitution using haemato-
poietic tumour cells may be an intrinsic feature of haematopoietic
malignancies.
In addition to a faster growth rate, the tumours that arose from
SCLC SP cells showed a significant degree of neo-angiogenesis.
These tumours, the corresponding SP fraction cells and tumours
that arose from these cells showed upregulation of VEGF, a feature
not previously reported for these cells. Side population-sorted cells
also reconstituted the entire cell population within 2 week in
culture, a feature consistent with efficient self-renewal, which is an
essential characteristic of cancer stem cell-like cells. In addition,
the SP cells overexpressed NANOG and SOX2, genes associated
with self-renewal process.
As non-SP fraction cells also formed tumours, although at a
significantly reduced rate and with delayed tumour growth rates, it
is possible that sorting SP cells, as defined by Verapamil gating, do
not permit absolute selection, and a few cells in non-SP fraction
have the capacity of dye efflux. This was confirmed in the self-
renewal experiments. Cells sorted from the non-SP fraction after
2 weeks in culture acquired 0.6–0.8% of cells that were able to
efflux the dye. Thus, it is not possible to achieve complete
separation of dye by excluding cells in a single sorting passage by
flow cytometry, and the non-SP fraction is likely to contain a small
percentage of cells that can also efflux the dye. Thus, the SP
fraction analysis needs to be compared with other methods,
including staining for ALDH. Alternatively, efflux of Hoechst dye
is only one of the many functional characteristics of tumor-
initiating cells. Previous reports indicate that haematopoietic stem
cells are also present in the non-SP compartment (Morita et al,
2006), and mammary repopulating cells have also been found in
the non-SP fraction. Thus, these compartments are not strictly
defined in normal organs, and some overlap is expected.
These considerations prompted us to undertake an extensive
search for additional cell surface and genetic markers to define
further the cancer stem-like cell population in the SP fraction. In
spite of the extensive search, we could not identify any common
surface markers that would be enriched in the SP fraction of all
SCLC cell lines we examined. However, we observed a consistent
decrease in SP cells in two markers, CD56 and CD90. These cell
markers represent features associated with neuronal differentia-
tion of SCLC and other organs, and their low expression is
consistent with the primitive nature of SP cells. CD56 (N-CAM,
neural cell adhesion molecule 1 isoform) is a hallmark of SCLC.
CD90 (Thy-1) is a neuronal and mesenchymal stem cell marker
that also defines the neuronal differentiation of these neuroendo-
crine tumours. In contrast to our data using SCLC, cell surface
expression of Thy-1 was reported to be enriched in CD133þ
tumour stem cells from brain tumours (Liu et al, 2006; Mizrak
et al, 2008) characterised by self-renewal, high proliferative
capacity in vitro and tumour reconstitution in vivo (Al Hajj
et al, 2003; Ponti et al, 2005; Sales et al, 2007; Eramo et al, 2008).
However, we found no change in frequency or enrichment in any
of the previously identified cell surface markers, including CD133,
in the SP fraction cells in SCLC cells. This may reflect high
expression of CD133 in H146 and H82 cells (20% and 90%,
respectively). Thus, stem-like cells from SCLC have features
similar to the haematopoietic malignancies, with enrichment in
SP fraction, rather than expression of cell surface markers
described for other solid tumours.
Number of mice with tumours/
number of xenografts (%)
Cell number SP fraction Non-SP fraction P value*
50 6/8 (75) 0/8 (0) 0.02
100 10/10 (100) 6/8 (75) 0.18
500 7/9 (78) 5/9 (56) 0.37
1000 8/10 (80) 7/10 (70) 1.00
* Determined by two-sided Fisher's exact test.
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Figure 3 Tumorigenicity of SP and non-SP cells in vivo.( A) In total, 50
(circles), 100 (triangles) and 500 (squares) H146 cells were implanted in
triplicate injections and tumour growth rates of SP cells (dashed lines, open
symbols) and non-SP cells (solid lines, closed symbols) were monitored
biweekly. The lines represent the average tumour volume calculated from
one experiment, as indicated in Materials and Methods. (B) Summary of
H146 tumours formed following implantation of the indicated cell numbers
from SP and non-SP cells from four independent experiments. Small
tumours that were only palpable (o5mm
2) were scored as positive.
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sABCG2 transporter expression is associated with drug resistance
and Hoechst dye efflux (Farnie and Clarke, 2007; Ho et al, 2007).
We did not detect an increase in ABCG2 transporter protein on cell
surface. However, gene expression analysis showed upregulation of
mRNA for the ABCG2 transporter. These changes were subse-
quently confirmed by independent RT–PCR. The previously
reported rapid membrane turnover of ABC transporters may be
responsible for this phenomenon (Robey et al, 2007).
Of significance, SP fraction cells showed upregulation of genes
that werepreviously associated with normal stem cell biology and
pluripotency. Similar to our observations, transcriptional profiling
of SP cells from several non-malignant tissues showed that more
genes were upregulated than downregulated and included genes
associated with multi-drug resistance, regulation of transcription,
cell signalling, Notch and Wnt pathways (Liadaki et al, 2005;
Behbod et al, 2006; Larderet et al, 2006). Side population fraction
cells examined in our studies have upregulated genes that are
involved in pathways modulating stemness, including MYC, FGF1,
OCT4, KLF4, NOTCH2 and WNT. These data confirm that SCLC
cell lines contain a population of highly undifferentiated cells with
stem cell-like characteristics.
Development of agents that target the Hedgehog pathway, which
is re-activated in bronchial mucosa following epithelial injury and
in progenitor cells (Watkins et al, 2003; Vestergaard et al, 2006),
renewed the interest in using these agents in treatment of SCLC.
Recent studies showed that stem-like cells in brain tumours are
selectively vulnerable to agents inhibiting the Notch pathway (Fan
et al, 2006). The feasibility of similar approaches in SCLC remains
to be established.
In summary, our findings identified a small population of SCLC
cells that resides in the SP fraction and has functional and
molecular features consistent with cancer stem cells. Further
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Figure 4 Tumours arising from SP fraction cells a have higher degree of angiogenesis. (A) Microvessel staining using mouse anti-CD31 antibodies of one
representative field from tumours generated from 500 non-SP (upper panel) and 500 SP (lower panel) H146 cells. H&E staining for each tumour is showed
on the right. (B) Computer-generated quantitative analysis of anti-CD31 staining fluorescence intensity from one representative tumour. Non-SP (filled bars)
and SP (open bars). Bars represent s.d. from 9–10 computer-generated random fields from three slides from one representative tumour. The
measurements are from one of two individual tumours±s.d.
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scharacterisation of their genetic signature, epigenetics and
metabolic features could have direct therapeutic implications.
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